Get the Stockscreener App
518.58
0.37%
1.89
Pre-market:
519.85
1.27
+0.24%
Madrigal Pharmaceuticals Inc stock is traded at $518.58, with a volume of 153.84K.
It is up +0.37% in the last 24 hours and up +1.55% over the past month.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
See More
Previous Close:
$516.69
Open:
$512.6
24h Volume:
153.84K
Relative Volume:
0.44
Market Cap:
$11.90B
Revenue:
$958.40M
Net Income/Loss:
$-288.28M
P/E Ratio:
-40.31
EPS:
-12.8641
Net Cash Flow:
$-193.02M
1W Performance:
-2.00%
1M Performance:
+1.55%
6M Performance:
+23.00%
1Y Performance:
+52.17%
1-Day Range:
$501.59
$519.05
1-Week Range:
$500.97
$535.29
52-Week Range:
$265.00
$615.00
Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile
Name
Madrigal Pharmaceuticals Inc
Sector
Industry
Phone
404-380-9263
Address
200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA
Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MDGL
Madrigal Pharmaceuticals Inc
|
518.58 | 11.85B | 958.40M | -288.28M | -193.02M | -12.86 |
VRTX
Vertex Pharmaceuticals Inc
|
423.24 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
686.36 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
776.02 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
301.19 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
290.80 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-06-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Nov-05-25 | Upgrade | Cantor Fitzgerald | Neutral → Overweight |
| Nov-03-25 | Upgrade | BofA Securities | Underperform → Neutral |
| Oct-15-25 | Initiated | Truist | Buy |
| Sep-04-25 | Resumed | H.C. Wainwright | Buy |
| Feb-28-25 | Upgrade | B. Riley Securities | Neutral → Buy |
| Feb-27-25 | Reiterated | H.C. Wainwright | Buy |
| Jun-28-24 | Initiated | Cantor Fitzgerald | Neutral |
| Jun-11-24 | Initiated | Wolfe Research | Outperform |
| Apr-22-24 | Initiated | BofA Securities | Underperform |
| Mar-15-24 | Upgrade | B. Riley Securities | Sell → Neutral |
| Mar-06-24 | Initiated | Citigroup | Buy |
| Feb-26-24 | Downgrade | B. Riley Securities | Neutral → Sell |
| Dec-20-22 | Reiterated | Oppenheimer | Outperform |
| Dec-19-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-19-22 | Reiterated | Piper Sandler | Overweight |
| Dec-19-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Jul-08-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| May-20-21 | Resumed | Goldman | Buy |
| Nov-24-20 | Resumed | Evercore ISI | Outperform |
| Nov-06-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-20 | Initiated | Piper Sandler | Overweight |
| Jun-05-20 | Initiated | BMO Capital Markets | Market Perform |
| May-05-20 | Initiated | Chardan Capital Markets | Buy |
| Jan-30-20 | Initiated | Canaccord Genuity | Buy |
| Jan-09-20 | Upgrade | UBS | Neutral → Buy |
| Nov-07-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-25-19 | Initiated | Stifel | Hold |
| Jun-10-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Feb-28-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-22-19 | Initiated | SVB Leerink | Outperform |
| Jan-23-19 | Initiated | UBS | Neutral |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Dec-12-18 | Initiated | B. Riley FBR | Neutral |
| Nov-19-18 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Nov-16-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Sep-04-18 | Initiated | Citigroup | Buy |
| Aug-06-18 | Downgrade | Goldman | Buy → Neutral |
| Jun-28-18 | Initiated | Raymond James | Mkt Perform |
View All
Madrigal Pharmaceuticals Inc Stock (MDGL) Latest News
Madrigal (MDGL) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release - Yahoo! Finance Canada
MDGL stock surges most in a month on Eli Lilly buyout speculation - MSN
Madrigal to Report Q1 2026 Results May 6, Host Webcast - MyChesCo
Madrigal Pharmaceuticals Reclassifies Board Ahead of 2026 Meeting - TipRanks
Madrigal Pharmaceuticals (NASDAQ: MDGL) reshapes Board classes ahead of 2026 meeting - Stock Titan
Madrigal Pharmaceuticals: Boom Or Bust In MASH? Regretfully, I'm Bearish (NASDAQ:MDGL) - Seeking Alpha
Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN
Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead. - BioPharma Dive
Madrigal Pharmaceuticals gains amid renewed takeover speculation - MSN
Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat - MSN
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: A 31% Upside Potential in the Biotech Arena - DirectorsTalk Interviews
Here are the most and least likely M&A targets in biotech, according to Truist - MSN
Madrigal Grants Equity Awards to 12 New Employees - MyChesCo
Universal Beteiligungs und Servicegesellschaft mbH Increases Stock Position in Madrigal Pharmaceuticals, Inc. $MDGL - MarketBeat
Madrigal outlines robust 2026 net sales growth and expanding pipeline amid 50% MASH market surge - MSN
Madrigal Pharmaceuticals - The Pharma Letter
Lobbying Update: $380,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock Price Passes Above 200 Day Moving AverageHere's Why - MarketBeat
Madrigal Pharmaceuticals (MDGL) Stock Movers | Q4 2025: Earnings Fall ShortGuidance Downgrade - Xã Châu Thành
Madrigal brings in medical affairs chief amid Rezdiffra rollout - The Pharma Letter
Madrigal Pharma Stock Sees Buyout Hype – Retail Predicts ‘Huge’ Deal On Liver Disease Drug Momentum - MSN
Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026 - The Manila Times
Liquidity Mapping Around (MDGL) Price Events - Stock Traders Daily
Madrigal Pharmaceuticals Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
12 new Madrigal hires get stock awards that vest over four years - Stock Titan
Madrigal Pharmaceuticals Grants Equity Awards to 76 New Employees - MSN
Madrigal Pharmaceuticals (MDGL) Stock: Is It Approaching Breakout Zone (-0.71%) 2026-04-20Real Trader Network - Xã Thanh Hà
Madrigal Pharmaceuticals, Inc. (MDGL) Stock Analysis: 26% Potential Upside Fuels Investor Interest - DirectorsTalk Interviews
Madrigal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Mixed Performance Indicators - Markets Mojo
Madrigal Pharmaceuticals Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
Lobbying Update: $120,000 of MADRIGAL PHARMACEUTICALS INC. lobbying was just disclosed - Quiver Quantitative
Madrigal wins European MASH approval as Novo rivalry looms - MSN
Madrigal Pharmaceuticals (NASDAQ:MDGL) Share Price Crosses Above 200 Day Moving AverageTime to Sell? - MarketBeat
Madrigal Grants Equity Awards to 20 New Employees - MyChesCo
What makes Madrigal Pharma (MDGL) one of the shorted biotech stocks to buy - MSN
Madrigal Pharmaceuticals Inc Stock (MDGL) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.39%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):